Enanta Pharmaceuticals Upgraded to “Outperform” at Zacks (ENTA)
Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a note issued to investors on Wednesday. The firm currently has a $47.10 target price on the stock. Zacks‘s target price points to a potential upside of 20.37% from the company’s current price.
ENTA has been the subject of a number of other recent research reports. Analysts at JMP Securities downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. Analysts at Robert W. Baird downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, June 24th. They now have a $41.00 price target on the stock. They noted that the move was a valuation call. Two research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $44.03.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 0.18% during mid-day trading on Wednesday, hitting $39.20. The stock had a trading volume of 325,820 shares. Enanta Pharmaceuticals has a 52-week low of $18.21 and a 52-week high of $46.443. The stock has a 50-day moving average of $39.89 and a 200-day moving average of $38.34. The company has a market cap of $726.3 million and a price-to-earnings ratio of 21.07.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, August 11th. The company reported $2.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.94. The company had revenue of $42.10 million for the quarter, compared to the consensus estimate of $40.83 million. The company’s revenue for the quarter was up 2531.3% on a year-over-year basis. On average, analysts predict that Enanta Pharmaceuticals will post $1.35 earnings per share for the current fiscal year.
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.